Fig. 1

Representative maximum intensity projection (MIP) [¹⁸F]FDOPA-L PET images of the same subject without evidence of disease (group 1) scanned after administration of [¹⁸F]FDOPA-L (A) and [¹⁸F]FDOPA-H (B). Below is an example of a subject in group 3 with liver metastases scanned with [¹⁸F]FDOPA-L (C) and [¹⁸F]FDOPA-H (D). Only existing liver lesions were used for evaluation. A small new site of focal uptake was noted in a mesentery lymph node 20 months after the initial scan